{"id":"33246b10-f5b1-5dc8-9654-fed488bb4ee8","stable_key":"c156003d-8cdf-5259-8561-9803795ecc82:nr-nad","predicate":"increases","statement":"Oral nicotinamide riboside increased the measured cardiac NAD+ pool in the two-hit HFpEF study.","claim_class":"mechanistic","status":"source_derived_draft","evidence_grade":"ungraded","direction":"positive","is_public":true,"mechanism_event_id":"3a1be55c-8385-50ec-a170-cd1abfb27de4","mechanism_event_label":"nr nad","subject":{"id":"7bb72d0e-e20d-51bc-b88b-7ff29dc2ad4a","slug":"nicotinamide-riboside","display_name":"Nicotinamide riboside","entity_type_key":"small_molecule"},"object":{"id":"9fa3820a-7fcf-5369-9d6a-afb755a22487","slug":"mouse-cardiac-nad-pool","display_name":"Mouse cardiac NAD+ pool","entity_type_key":"cellular_process"},"evidence_count":1,"mechanism_event":{"id":"3a1be55c-8385-50ec-a170-cd1abfb27de4","stable_key":"c156003d-8cdf-5259-8561-9803795ecc82:nr-nad","event_type":"increases","label":"nr nad","description":"Model-specific finding; read linked claim context and source-access tier.","status":"provisional","compartment":null,"participants":[{"entity":{"id":"7bb72d0e-e20d-51bc-b88b-7ff29dc2ad4a","slug":"nicotinamide-riboside","display_name":"Nicotinamide riboside","entity_type_key":"small_molecule"},"role":"subject","stoichiometry":null,"state_label":"","sequence_order":0,"notes":""},{"entity":{"id":"9fa3820a-7fcf-5369-9d6a-afb755a22487","slug":"mouse-cardiac-nad-pool","display_name":"Mouse cardiac NAD+ pool","entity_type_key":"cellular_process"},"role":"target","stoichiometry":null,"state_label":"","sequence_order":1,"notes":""},{"entity":{"id":"283ed24b-06a1-50aa-9281-df3bac6ce37e","slug":"nad-plus","display_name":"NAD+","entity_type_key":"small_molecule"},"role":"measured metabolite","stoichiometry":null,"state_label":"","sequence_order":2,"notes":""}]},"contexts":[{"dimension":"access_level","value_text":"full_text_and_supplement_review","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"compartment","value_text":"Cardiac tissue / mitochondria","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"dose","value_text":"400 mg/kg/day","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"duration","value_text":"Figure 2 treatment timeline; exact intervention duration not independently resolved from narrative","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"endpoint","value_text":"mouse-cardiac-nad-pool","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"evidence_location","value_text":"NAD+ assay kit; Figure 2I","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"experimental_model","value_text":"Mouse two-hit HFpEF model: 60% fat-calorie diet plus L-NAME 0.5 g/L drinking water; additional intervention as stated","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"exposure","value_text":"nicotinamide-riboside","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"limitations","value_text":"Single primary study; not independently replicated here. Cardiac and recombinant findings do not establish pulmonary endothelial, viral-sepsis or ARDS effects.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"nutrient_topic","value_text":"Topical cross-reference only; no inheritance of another actor's effects.","comparator":null,"unit":null,"notes":"","entity":{"slug":"nad-plus","display_name":"NAD+","entity_type_key":"small_molecule"}},{"dimension":"organism","value_text":"Mus musculus","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"plain_language","value_text":"Oral nicotinamide riboside increased the measured cardiac NAD+ pool in the two-hit HFpEF study.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"primary_locator","value_text":"[{\"cache\": \"artifacts/dlat-curation/heart-blocks.json\", \"block_index\": 25, \"text_sha256\": \"1814242d6194ed4e0b3ab78287e20f85b6bc243051183d0f24d9034c3a930257\", \"xml_element_id\": null}, {\"cache\": \"artifacts/dlat-curation/heart-blocks.json\", \"block_index\": 26, \"text_sha256\": \"61dd26202087c725d9dc65345339778ed43192b3f765d05fa8a311a6e1944b34\", \"xml_element_id\": \"Par11\"}, {\"cache\": \"artifacts/dlat-curation/heart-blocks.json\", \"block_index\": 72, \"text_sha256\": \"2b1ada63fe6c48d4296bbfb14a97940ac4a866b1d5171b0923851ec72f88ab15\", \"xml_element_id\": \"Par31\"}]","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"primary_references","value_text":"https://doi.org/10.1038/s41467-026-70703-w","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"route","value_text":"Oral gavage","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"sample_size","value_text":"6 per group","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"tissue_or_cell_type","value_text":"Cardiac tissue and cardiomyocytes","comparator":null,"unit":null,"notes":"","entity":null}],"evidence":[{"id":"4a23e0d9-48e9-50bb-a8b7-4a4d82539ffe","evidence_kind":"source_excerpt","locator":"Lines 513-529","start_line":513,"end_line":529,"excerpt":"Oral nicotinamide riboside increased the measured cardiac NAD+ pool in the two-hit HFpEF study.\norganism: Mus musculus\ntissue_or_cell_type: Cardiac tissue and cardiomyocytes\nexperimental_model: Mouse two-hit HFpEF model: 60% fat-calorie diet plus L-NAME 0.5 g/L drinking water; additional intervention as stated\ncompartment: Cardiac tissue / mitochondria\ndose: 400 mg/kg/day\nduration: Figure 2 treatment timeline; exact intervention duration not independently resolved from narrative\nroute: Oral gavage\nprimary_references: https://doi.org/10.1038/s41467-026-70703-w\naccess_level: full_text_and_supplement_review\nevidence_location: NAD+ assay kit; Figure 2I\nendpoint: mouse-cardiac-nad-pool\nexposure: nicotinamide-riboside\nlimitations: Single primary study; not independently replicated here. Cardiac and recombinant findings do not establish pulmonary endothelial, viral-sepsis or ARDS effects.\nprimary_locator: [{\"cache\": \"artifacts/dlat-curation/heart-blocks.json\", \"block_index\": 25, \"text_sha256\": \"1814242d6194ed4e0b3ab78287e20f85b6bc243051183d0f24d9034c3a930257\", \"xml_element_id\": null}, {\"cache\": \"artifacts/dlat-curation/heart-blocks.json\", \"block_index\": 26, \"text_sha256\": \"61dd26202087c725d9dc65345339778ed43192b3f765d05fa8a311a6e1944b34\", \"xml_element_id\": \"Par11\"}, {\"cache\": \"artifacts/dlat-curation/heart-blocks.json\", \"block_index\": 72, \"text_sha256\": \"2b1ada63fe6c48d4296bbfb14a97940ac4a866b1d5171b0923851ec72f88ab15\", \"xml_element_id\": \"Par31\"}]\nplain_language: Oral nicotinamide riboside increased the measured cardiac NAD+ pool in the two-hit HFpEF study.\nsample_size: 6 per group","model_system":"Mouse two-hit HFpEF model: 60% fat-calorie diet plus L-NAME 0.5 g/L drinking water; additional intervention as stated","directness":"reported_statement","verification_status":"source_derived_draft","notes":"Quotation is the authored curation, not original publisher wording. Exact primary locators and access limits retained in contexts.","relationship":"supports","weight":1.0,"link_notes":"","source":{"id":"ee72956d-4fd4-58d3-9a94-e173bb1e3282","stable_key":"import-c156003d-8cdf-5259-8561-9803795ecc82","title":"DLAT: cardiac fatty-acid oxidation and mitochondrial glutathione evidence","document_type":"imported_text","citation_label":"AI-assisted two-paper curation, 2026-09-20. Cardiac full-text/supplement review; CRC abstract only. No pulmonary endothelial validation.","file_path":"","sha256":"159e5472c8b1d104625f9c648dc9ee24dcd5fe102109fd960bba50e9ba9de954","revision_id":"5ca6b1f1-fd75-5f8d-ba2b-0215fbf387c7","review_status":"unverified_draft","notes":""}}],"relations":[],"conflicts":[],"corrections":[],"research":null}